• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.

作者信息

Azuno Y, Kaneko T, Nishimura M, Okuya S, Nakai K, Nomiyama J, Mori K, Okafuji K, Okubo M, Matsutani A, Kamei S, Zaitsu Y, Takeuchi Y, Oka Y, Kaku K

机构信息

Department of Internal Medicine, Yamaguchi Rosai Hospital, Japan.

出版信息

Bone Marrow Transplant. 1996 Jul;18(1):257-9.

PMID:8832032
Abstract

We present a female patient who received an allogeneic bone marrow transplantation for primary refractory Philadelphia-positive acute biphenotypic leukemia. Since leukemic blasts were persistently present in peripheral blood and bone marrow, in spite of the evidence for engraftment of male donor hematopoiesis, we performed donor leukocyte transfusions and discontinued immunosuppression. An initial complete remission was obtained 15 weeks after allogeneic bone marrow transplantation, and lasted for 24 weeks. We concluded that the prominent mechanism for the eradication of the refractory leukemic clone in the patient was the graft-versus-leukemia effect.

摘要

相似文献

1
Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
Bone Marrow Transplant. 1996 Jul;18(1):257-9.
2
[Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation].
Rinsho Ketsueki. 2004 Sep;45(9):1044-7.
3
Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.在费城染色体阳性急性淋巴细胞白血病患者中,通过诱导异基因干细胞移植后的移植物抗宿主病来清除残留的bcr-abl阳性克隆。
Bone Marrow Transplant. 2002 Jan;29(1):63-6. doi: 10.1038/sj.bmt.1703318.
4
[Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].[113名处于第二次缓解期的儿童急性淋巴细胞白血病患者接受异基因骨髓移植与自体移植的对比研究。西班牙儿童骨髓移植协作组(GETMON)的研究结果]
Sangre (Barc). 1996 Apr;41(2):101-8.
5
[Allogeneic bone marrow transplantation in a case of acute lymphoblastic leukemia with positive Philadelphia chromosome].[费城染色体阳性急性淋巴细胞白血病患者的异基因骨髓移植]
Rinsho Ketsueki. 1989 May;30(5):680-5.
6
Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.供体白细胞层输注与化疗用于骨髓移植后复发的白血病
Haematologica. 1995 Jul-Aug;80(4):338-40.
7
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].[使用来自同一供体的异基因外周血干细胞进行减低强度干细胞移植治疗骨髓移植后复发的白血病]
Rinsho Ketsueki. 2006 Jul;47(7):639-44.
8
A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT.
Am J Hematol. 2002 Sep;71(1):37-40. doi: 10.1002/ajh.10166.
9
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.伊马替尼(STI571)与异基因干细胞移植治疗Ph+难治性急性淋巴细胞白血病的良好疗效。
Bone Marrow Transplant. 2002 Dec;30(12):971-3. doi: 10.1038/sj.bmt.1703760.
10
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.成年急性淋巴细胞白血病患者异基因造血干细胞移植的结果:首次完全缓解时,亲属供者移植与非亲属供者移植无差异。
J Clin Oncol. 2004 Jul 15;22(14):2816-25. doi: 10.1200/JCO.2004.07.130.